JPAD-Journal of Prevention of Alzheimers Disease

Papers
(The TQCC of JPAD-Journal of Prevention of Alzheimers Disease is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats436
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217236
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France227
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia207
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice98
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations79
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data68
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort50
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation48
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use47
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease43
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings38
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease35
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review33
Informal care for people with dementia in Europe33
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system32
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias28
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease24
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment23
The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test23
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration22
Introduction to the Special Issue on the A4 Study20
Donanemab: Appropriate use recommendations20
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status20
Independent and Joint Associations of Socioeconomic Status and Lifestyle behaviors with Cognitive Impairment among Elderly Chinese Population20
Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities19
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese19
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease17
In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum16
Aducanumab: Appropriate Use Recommendations16
Are Population-Level Approaches to Dementia Risk Reduction Under-Researched? A Rapid Review of the Dementia Prevention Literature16
Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Older Adults with Normal Cognition or Mild Cognitive Impairment16
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?15
Global Burden of Dementia Death from 1990 to 2019, with Projections to 2050: An Analysis of 2019 Global Burden of Disease Study15
Longitudinal Impacts of Precision Greenness on Alzheimer's Disease14
Erratum to: Alzheimer's Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease13
Cardiovascular-kidney-metabolic syndrome and incidence of dementia among older adults13
The Therapeutic Effects of Noninvasive Brain Stimulation Combined with Cognitive Training in Elders with Alzheimer's Disease or Amnesic Mild Cognitive Impairment12
Programmed Death of Microglia in Alzheimer's Disease: Autophagy, Ferroptosis, and Pyroptosis12
Can Virtual Scientific Conferences Facilitate Two-Way Learning between Dementia Researchers and Participants?12
Erratum to: Education as Risk Factor of Mild Cognitive Impairment: The Link to the Gut Microbiome12
Disease-Modifying Antirheumatic Drugs and Dementia Prevention: A Systematic Review of Observational Evidence in Rheumatoid Arthritis12
Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions12
Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A411
16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24–27, 2023: Posters11
The Causal Relationship between Genetically Predicted Biological Aging, Alzheimer's Disease and Cognitive Function: A Mendelian Randomisation Study11
Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform11
Association of Vascular Endothelial Growth Factor Levels with Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis11
Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy10
Erratum to: Digital Clock Drawing as an Alzheimer's Disease Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in Older Adults10
Reproductive Markers in Alzheimer's Disease Progression: The Framingham Heart Study10
Modulatory Effect of Blood LDL Cholesterol on the Association between Cerebral Aβ and Tau Deposition in Older Adults10
Serum Tau-A and Tau-C Levels and Their Association with Cognitive Impairment and Dementia Progression in a Memory Clinic Derived Cohort10
Where Do We Go from Here?10
Reply to Letter to the Editor: “Early-Onset Type 2 Diabetes and Risk of Dementia”10
Plasma amyloid-β precursor protein 669–711/amyloid-β1–42 ratio is associated with cognition in Alzheimer's disease10
Effectiveness of Physical Exercise on Alzheimer's disease. A Systematic Review10
Development of a Mobile-First Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies9
Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults9
Basal forebrain global functional connectivity is preserved in asymptomatic presenilin-1 E280A mutation carriers: Results from the Colombia cohort9
A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice9
Associations of early-onset coronary heart disease and genetic susceptibility with incident dementia and white matter hyperintensity: A prospective cohort study9
Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabece9
Corrigendum to “17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: Symposia, Oral Communications” [J Prev Alzheimers Dis 2025;12(1S):100043].9
Data-Driven Thresholding Statistically Biases ATN Profiling across Cohort Datasets9
The ‘Aducanumab Story': Will the Last Chapter Spell the End of the ‘Amyloid Hypothesis' or Mark a New Beginning?8
Cardiovascular health, genetic predisposition, and dementia risk among atherosclerotic cardiovascular disease patients8
Current Themes and Controversies in the Alzheimer's Disease Field: Looking Ahead to the CTAD Meeting in San Francisco, November 29–December 2 20228
Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study8
The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry8
Representation of Racial and Ethnic Minority Populations in Dementia Prevention Trials: A Systematic Review8
Major Cost Drivers in Assessing the Economic Burden of Alzheimer's Disease: A Structured, Rapid Review7
Interest in and Experience with Genetic Testing for Late-Onset Medical Conditions: Results from the National Poll on Healthy Aging7
17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 20247
Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study7
“Back to Braak”: Role of Nucleus Reuniens and Subcortical Pathways in Alzheimer's Disease Progression7
Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease7
The Association between Sugar-Sweetened Beverages and Cognitive Function in Middle-Aged and Older People: A Meta-Analysis7
Chinese Preclinical Alzheimer's Disease Study (C-PAS): Design and Challenge from PET Acceptance7
The Association between Peanut and Peanut Butter Consumption and Cognitive Function among Community-Dwelling Older Adults7
Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry)7
The Clinical Trials Alzheimer's Disease (CTAD) Meeting in San Francisco, Fall 2022, Will Be a Very Exciting Event!7
Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis7
Feasibility of computerized motor, cognitive and speech tests in the home: Analysis of TAS Test in 2,300 older adults7
Brain photobiomodulation: a potential treatment in Alzheimer’s and Parkinson’s diseases7
Mechanisms Underlying Non-Pharmacological Dementia Prevention Strategies: A Translational Perspective7
The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland7
Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force6
Association of Preeclampsia with Incident Dementia and Alzheimer's Disease among Women in the Framingham Offspring Study6
First Experiences with Amyloid-Related Imaging Abnormalities — Yet without Imaging that Can Rule Out Cerebral Injury or Monitor Efficacy of Recommended Management6
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force6
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)6
Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats6
Fingolimod ameliorates amyloid deposition and neurodegeneration in APP/PS1 mouse model of Alzheimer's disease6
Consistency between Treatment Effects on Clinical and Brain Atrophy Outcomes in Alzheimer's Disease Trials6
Relationships of Hypnotics with Incident Dementia and Alzheimer's Disease: A Longitudinal Study and Meta-Analysis6
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration6
Association of Multi-Domain Factors with Cognition in the UK Biobank Study6
Posters6
Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report6
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease6
Universal Prevention of Dementia in Italy: A Document Analysis of the 21 Italian Regional Prevention Plans6
Symposia — Oral Communications — Late Breaking News6
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform6
Determinants of Medical Direct Costs of Care among Patients of a Memory Center6
Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease6
The role of serum vitamins in mediating the effect of neurodegenerative diseases on subcortical brain volume5
How Will Aducanumab Approval Impact AD Research?5
Embryo Selection for a Carrier of an Early-Onset Alzheimer's Disease-Associated Mutation in the PSEN1 Gene5
Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults5
Decreased Gray—White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea5
«Compounded Interest» in Alzheimer's Disease: Do New Amyloid-Targeting Treatments Justify Their Use5
The Dawn of a New Era of Alzheimer's Research and Drug Development5
Latent cognitive profiles and their associations with instrumental activities of daily living among older adults without dementia: A United States national cross-sectional study5
Peripheral Blood BRCA1 Methylation Positively Correlates with Major Alzheimer's Disease Risk Factors5
Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials5
Reducing the Effects of Ageing on Cognition with Therapeutic Intervention of an Oral Multi-Nutrient: The REACTION Pilot Trial Study Design5
Visual Event-Related Potentials under External Emotional Stimuli as Early Signs for Mild Cognitive Impairment5
Higher Cognitive Reserve Is Beneficial for Cognitive Performance Via Various Locus Coeruleus Functional Pathways in the Pre-Dementia Stage of Alzheimer's Disease5
A Fay-Herriot Model for Estimating Subjective Cognitive Decline among Military Veterans5
Alzheimer's Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners5
Environmental Distractions during Unsupervised Remote Digital Cognitive Assessment5
The Future is Now: Advancing Blood-Based Markers5
Flavonoid-Rich Fruit Intake in Midlife and Late-Life and Associations with Risk of Dementia: The Framingham Heart Study5
Left Frontoparietal Control Network Connectivity Moderates the Effect of Amyloid on Cognitive Decline in Preclinical Alzheimer's Disease: The A4 Study5
Prevention of Alzheimer's Disease and Cognitive Decline with Diet & Lifestyle: Proceedings of the A. G. Leventis Foundation Conference5
Aducanumab: Appropriate Use Recommendations5
Unveiling Potential Biomarkers in Cerebrospinal Fluid for Amyloid Pathological Positivity in Non-Demented Individuals5
Anti-Hypertensive Drugs Moderate the Relationship of Blood Pressure with Alzheimer's Pathologies and Neurodegenerative Markers in Non-Demented Hypertensive Older Adults4
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial4
Baseline habitual dietary nitrate intake and Alzheimer's Disease related neuroimaging biomarkers in the Australian Imaging, Biomarkers and Lifestyle study of ageing4
Lifestyle factors and plasma biomarkers of Alzheimer's disease: A narrative review4
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 20214
Preventing dementia in Italy: Estimations of modifiable risk factors and public health implications4
Assessing the causal role of lipid metabolites in Alzheimer's disease: A mendelian randomization study4
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients4
Early-Onset Type 2 Diabetes and Risk of Dementia4
China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress4
Implications of Emerging Uses of Genetic Testing for Alzheimer's Disease4
A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease4
Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults4
Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States4
Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylat4
Reply to: Mitochondrial dysfunction as the missing link between circadian syndrome and dementia4
Associations and Potential Multiple Mechanisms between Subjective Hearing Loss and Cognitive Impairment4
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease4
Motor abilities and cognitive performance in Latinos with autosomal dominant Alzheimer's disease4
Current status and future directions for the diagnosis and management of mild cognitive impairment in Southeast Asia: A SEACURE consensus paper4
Opposite causal effects of type 2 diabetes and metformin on Alzheimer's disease4
Associations of ischemic heart disease with brain glymphatic MRI indices and risk of Alzheimer's disease4
At a Glance: An Update on Neuroimaging and Retinal Imaging in Alzheimer's Disease and Related Research4
Microglial activation states and their implications for Alzheimer's Disease4
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies4
High Intake of Dietary Cholesterol Decreases the Risk of All-Cause Dementia and AD Dementia: A Results from Framingham Offspring Cohort4
ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease P4
0.10165905952454